Ultragenyx Pharmaceutical RARE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
Based on trailing twelve months.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's return on equity?
- Ultragenyx Pharmaceutical (RARE) reported return on equity of -325.6% in Q3 2025.
- How has Ultragenyx Pharmaceutical's return on equity changed year-over-year?
- Ultragenyx Pharmaceutical's return on equity decreased by 10.2% year-over-year, from -295.5% to -325.6%.
- What is the long-term trend for Ultragenyx Pharmaceutical's return on equity?
- Over 4 years (2020 to 2024), Ultragenyx Pharmaceutical's return on equity has grown at a 79.6% compound annual growth rate (CAGR), from -20.6% to -214.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.